Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
SciSparc Ltd. is a biotechnology company focused on the development of cannabinoid-based therapies for various medical conditions. The company operates primarily in Israel and is leveraging its proprietary technology platform to create innovative treatments, which sets it apart in a competitive market characterized by rapid advancements and regulatory challenges.
SciSparc generates revenue primarily through collaborations with pharmaceutical companies and licensing its proprietary cannabinoid formulations. The company benefits from a unique position in the cannabinoid space, with a focus on clinical trials and regulatory pathways that enhance its credibility and potential for market entry.
Progress in clinical trials for cannabinoid therapies
Regulatory approvals for new products
Strategic partnerships with larger pharmaceutical firms
Market sentiment towards the biotech sector
Regulatory changes affecting the cannabis industry
Technological advancements by competitors in cannabinoid therapies
Emerging biotech firms with innovative cannabinoid products
Large pharmaceutical companies entering the cannabinoid space
High cash burn rate leading to potential liquidity issues
Dependence on external funding for R&D
low - The demand for biotech products is less sensitive to economic cycles, but funding for R&D can be affected by broader economic conditions.
Moderate - Rising interest rates may increase the cost of capital for R&D financing, potentially impacting the company's ability to fund its projects.
minimal - The company has low debt levels, reducing its sensitivity to credit market conditions.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant volatility, particularly given its recent performance trends.
